<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00759525</url>
  </required_header>
  <id_info>
    <org_study_id>2001-P-001404</org_study_id>
    <nct_id>NCT00759525</nct_id>
  </id_info>
  <brief_title>The Role of Mineralocorticoid Receptors in Vascular Function</brief_title>
  <official_title>The Role of Mineralocorticoid Receptors in Vascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to figure out how decreasing the activity of 11-beta
      hydroxysteroid dehydrogenase (11-beta HSD) will affect your blood vessel function. 11-beta
      HSD, which is found in the kidneys and blood vessels, is a natural protein that when active
      helps to keep your blood pressure under control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study intends to determine whether activation of mineralocorticoid receptors affects
      vascular function. Vascular function relies on two components of the blood vessel: the inner
      lining (endothelium) and the vascular smooth muscle. In specific aim 1, we seek to determine
      if that inhibition of the enzyme 11-beta hydroxysteroid dehydrogenase (11-beta-HSD) will
      impair endothelium-dependent vasodilation and/or vascular smooth muscle function.

      The syndrome of apparent mineralocorticoid excess (AME) is a rare disorder identified in
      approximately 50 individuals characterized by low-aldosterone hypertension, associated with
      low renin and hypokalemia These subjects avidly retain salt and water, have suppression of
      both plasma renin and aldosterone levels, but clinically appear as though they have a state
      of mineralocorticoid excess. A detailed series of investigations has elucidated the cause of
      this syndrome: severe attenuation of the enzyme 11 beta-hydroxysteroid dehydrogenase
      (11-beta-HSD). 11-beta-HSD converts cortisol, able to activate mineralocorticoid receptors to
      cortisone, which cannot. This abnormality can be identified by measuring an abnormal ratio of
      urinary breakdown products of cortisol and cortisone. Subjects with AME have a high ratio
      indicative of elevated cortisol concentrations.

      Although classical AME is a rare syndrome with a specific recessive inheritance, several
      other mutations have been identified which cause a varying severity of disease. Recent
      evidence has suggested mild abnormalities in this pathway may be much more common. In fact
      two studies have demonstrated that subjects with essential hypertension had greater levels of
      cortisol/cortisone urinary levels than matched controls. Thus, mild abnormalities of this
      enzyme may be an important contributor to a segment of patients with high blood pressure.
      Further, this is the pathway by which consumption of excess black licorice causes
      hypertension. Black licorice contains glycyrrhizic acid that selectively inhibits 11
      beta-HSD. Glycyrrhizic acid is used as a dietary sweetener and sold in &quot;health-food&quot; stores
      and may also play a epidemiological role in hypertension.

      Analogous to the renin-angiotensin system, 11-beta-HSD is not only found in the kidneys, but
      is found in both vascular endothelial (inner lining) and smooth muscle cells. Hypertension,
      similar to other risk factors for cardiovascular disease impairs vascular function. One of
      its major effects is decreasing the bioavailability of endothelium-derived nitric oxide.
      Nitric oxide contributes importantly to vascular homeostasis by modulating vascular tone,
      inhibiting both platelet aggregation and coagulation, and inhibition translocation of
      leukocytes into the vascular wall. Further, patients with hypertension have increased
      endothelin-1 production and receptor activation. Endothelin-1 antagonizes the beneficial
      activities of nitric oxide. Experimentally, inactivation of 11 beta-HSD in a rat model has
      been demonstrated to cause hypertension, increase endothelin receptor A activation and
      decrease bioavailability of endothelium-derived nitric oxide. Inhibition of mineralocorticoid
      receptors in this model prevents impairment of vascular function. Thus, in animal models,
      abnormalities in this pathway may not only cause hypertension, but create an environment
      favorable to the development and progression of atherosclerosis. Further, recent evidence
      suggests that activation of this pathway contributes importantly to the morbidity and
      mortality in patients with congestive heart failure. A large, randomized study demonstrated
      that a small dose of a mineralocorticoid inhibitor, spironolactone, substantially reduced
      morbidity and mortality in patients with severe heart failure. Experimentally, spironolactone
      improved vascular function in patients with congestive heart failure.

      Therefore, we seek to characterize the vascular effects of this pathway in humans. This
      submission involves one protocol: 1) to determine if reversible inhibition of 11 beta-HSD
      decreases the bioavailability of endothelium-derived nitric oxide and impairs vascular smooth
      muscle function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm Blood Flow</measure>
    <time_frame>Outcome was measured at the end of each study period (i.e. 14 days after Baseline measurements were taken)</time_frame>
    <description>At the end of each 14-day intervention (Glycyrrhinitic acid or Placebo), vascular endothelial function was assessed by measuring forearm blood flow and comparing to Baseline. The outcome measure depicted below reflects the change in forearm blood flow from Baseline after completing the glycyrrhinitic acid regimen as well as the change in forearm blood flow from Baseline after taking the matching placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Apparent Mineralocorticoid Excess (AME)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycyrrhetic Acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycyrrhetic Acid</intervention_name>
    <description>130 mg daily for fourteen days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>licorice root sweetener</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily for fourteen days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

        Exclusion Criteria:

          -  Blood pressure above 140/90

          -  Abnormal physical finding

          -  Blood test values for total and LDL cholesterol, CBC, sodium, potassium, creatinine,
             and glucose laboratories greater 1.5 times normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua A Beckman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Joshua+Beckman+mineralocorticoid</url>
    <description>Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans.</description>
  </link>
  <results_reference>
    <citation>Sobieszczyk P, Borlaug BA, Gornik HL, Knauft WD, Beckman JA. Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans. Clin Sci (Lond). 2010 Aug 5;119(10):437-42. doi: 10.1042/CS20100087.</citation>
    <PMID>20515440</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>August 15, 2013</results_first_submitted>
  <results_first_submitted_qc>May 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2015</results_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Joshua A. Beckman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
    <mesh_term>Mineralocorticoid Excess Syndrome, Apparent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineralocorticoids</mesh_term>
    <mesh_term>Glycyrrhetinic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glycyrrhetinic Acid First, Then Placebo</title>
          <description>Glycyrrhetic Acid-130 mg/day for 14 days followed by placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Glycyrrhetinic Acid</title>
          <description>Placebo followed by Glycyrrhetic Acid-130 mg/day for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Cross Over study</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forearm Blood Flow</title>
        <description>At the end of each 14-day intervention (Glycyrrhinitic acid or Placebo), vascular endothelial function was assessed by measuring forearm blood flow and comparing to Baseline. The outcome measure depicted below reflects the change in forearm blood flow from Baseline after completing the glycyrrhinitic acid regimen as well as the change in forearm blood flow from Baseline after taking the matching placebo.</description>
        <time_frame>Outcome was measured at the end of each study period (i.e. 14 days after Baseline measurements were taken)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycyrrhinitic Acid</title>
            <description>All of the 15 subjects received both glycyrrhinitic acid (130mg/day) (GA) for a 14-day period and placebo for a 14-day period. Approximately half of the subjects received GA before placebo; the other half received placebo before GA. There was a 2-week washout period between the two conditions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All of the 15 subjects received both glycyrrhinitic acid (130mg/day) (GA) for a 14-day period and placebo for a 14-day period. Approximately half of the subjects received GA before placebo; the other half received placebo before GA. There was a 2-week washout period between the two conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Forearm Blood Flow</title>
          <description>At the end of each 14-day intervention (Glycyrrhinitic acid or Placebo), vascular endothelial function was assessed by measuring forearm blood flow and comparing to Baseline. The outcome measure depicted below reflects the change in forearm blood flow from Baseline after completing the glycyrrhinitic acid regimen as well as the change in forearm blood flow from Baseline after taking the matching placebo.</description>
          <units>ml/100ml of tissue/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.26"/>
                    <measurement group_id="O2" value="1.34" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days.</time_frame>
      <desc>Subjects were queried concerning their catheter insertion site.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glycyrrhetinic Acid First, Then Placebo</title>
          <description>Healthy subjects without medical condition.</description>
        </group>
        <group group_id="E2">
          <title>Placebo First, Then Glycyrrhetinic Acid</title>
          <description>Healthy subjects without medical condition.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Creager, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-5267</phone>
      <email>mcreager@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

